{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:39:00Z","timestamp":1793342340440,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2023-18-90"],"award-info":[{"award-number":["320.6750.2023-18-90"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.modpat.2025.100935","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:17:49Z","timestamp":1769732269000},"page":"100935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)\u2013Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity"],"prefix":"10.1016","volume":"39","author":[{"given":"Jintao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Y.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9405-9665","authenticated-orcid":false,"given":"Gary M.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.modpat.2025.100935_bib1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"4785","key":"10.1016\/j.modpat.2025.100935_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.modpat.2025.100935_bib3","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1002\/cncr.25120","article-title":"Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer","volume":"116","author":"Chang","year":"2010","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.modpat.2025.100935_bib4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/bjs.5894","article-title":"Neoadjuvant chemotherapy for operable breast cancer","volume":"94","author":"Mieog","year":"2007","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.modpat.2025.100935_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1574887112666170202165049","article-title":"Neoadjuvant therapy for HER2-positive breast cancer","volume":"12","author":"Wuerstlein","year":"2017","journal-title":"Rev Recent Clin Trials"},{"issue":"3","key":"10.1016\/j.modpat.2025.100935_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/cco-20-123","article-title":"Neoadjuvant treatment for HER2-positive breast cancer","volume":"9","author":"Takada","year":"2020","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100935_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2025.100935_bib8","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100935_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2025.100935_bib10","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.modpat.2025.100935_bib11","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9938","key":"10.1016\/j.modpat.2025.100935_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.modpat.2025.100935_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100935_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","article-title":"Targeting HER2 heterogeneity in breast and gastrointestinal cancers","volume":"10","author":"Valenza","year":"2024","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.modpat.2025.100935_bib15","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/ijms19082158","article-title":"HER2 heterogeneity is associated with poor survival in HER2-positive breast cancer","volume":"19","author":"Hosonaga","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.modpat.2025.100935_bib16","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/1878-0261.12375","article-title":"Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors","volume":"12","author":"Rye","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.modpat.2025.100935_bib17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1186\/1471-2407-14-647","article-title":"Intratumoral heterogeneity impacts the response to anti-neu antibody therapy","volume":"14","author":"Song","year":"2014","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2025.100935_bib18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3892\/ol.2023.14021","article-title":"Predictors of successful neoadjuvant treatment in HER2-positive breast cancer","volume":"26","author":"H\u00e4nnik\u00e4inen","year":"2023","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.modpat.2025.100935_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-017-4453-8","article-title":"HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma","volume":"166","author":"Hou","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.modpat.2025.100935_bib20","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.modpat.2025.100935_bib21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.5858\/133.4.611","article-title":"Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines","volume":"133","author":"Vance","year":"2009","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"10.1016\/j.modpat.2025.100935_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41379-021-00738-5","article-title":"Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer","volume":"34","author":"Katayama","year":"2021","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2025.100935_bib23","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/cancers16051062","article-title":"High HER2 intratumoral heterogeneity is a predictive factor for poor prognosis in early-stage and locally advanced HER2-positive breast cancer","volume":"16","author":"Tanei","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.modpat.2025.100935_bib24","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3390\/cancers15102664","article-title":"HER2 intratumoral heterogeneity in breast cancer, an evolving concept","volume":"15","author":"Hou","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.modpat.2025.100935_bib25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1309\/AJCP51HCGPOPWSCY","article-title":"Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab","volume":"144","author":"Lee","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2025.100935_bib26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1654-1103.2005.tb02393.x","article-title":"Rao's quadratic entropy as a measure of functional diversity based on multiple traits","volume":"16","author":"Botta-Duk\u00e1t","year":"2005","journal-title":"J Veg Sci"},{"issue":"12","key":"10.1016\/j.modpat.2025.100935_bib27","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2025.100935_bib28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.modpat.2025.100935_bib29","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2025.100935_bib30","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jcp.2007.054866","article-title":"HER2 testing in the UK: further update to recommendations","volume":"61","author":"Walker","year":"2008","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2025.100935_bib31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/his.12412","article-title":"Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression","volume":"65","author":"Zhang","year":"2014","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.modpat.2025.100935_bib32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.clbc.2022.03.004","article-title":"Overall survival for HER2-positive breast cancer patients in the HER2-targeted era: evidence from a population-based study","volume":"22","author":"Marczyk","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"10.1016\/j.modpat.2025.100935_bib33","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"10390","key":"10.1016\/j.modpat.2025.100935_bib34","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"10371","key":"10.1016\/j.modpat.2025.100935_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.modpat.2025.100935_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.541","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100935_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.modpat.2025.100935_bib38","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.modpat.2025.100935_bib39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41467-019-14111-3","article-title":"Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade","volume":"11","author":"Bras\u00f3-Maristany","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.modpat.2025.100935_bib40","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1093\/annonc\/mdt364","article-title":"Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients","volume":"24","author":"Guarneri","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100935_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13059-015-0657-6","article-title":"Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification","volume":"16","author":"Ng","year":"2015","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100935_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-025-02138-6","article-title":"Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct Target Ther"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225002339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225002339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:41:52Z","timestamp":1775788912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395225002339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0893395225002339"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100935","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)\u2013Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100935"}}